公开(公告)号：US11919921B2

公开(公告)日：2024-03-05

申请号：US17748338

申请日：2022-05-19

申请人： Galecto Biotech AB

发明人： Thomas Brimert ,  Richard Johnsson ,  Hakon Leffler ,  Ulf Nilsson ,  Fredrik Zetterberg

IPC分类号： A61K31/7056 ,  A61K31/706 ,  C07H15/203 ,  C07H13/10 ,  C07H19/056 ,  C07H13/08 ,  C07H15/26 ,  C07H15/207 ,  C07H17/02

CPC分类号： C07H15/203 ,  A61K31/706 ,  A61K31/7056 ,  C07H13/08 ,  C07H13/10 ,  C07H15/207 ,  C07H15/26 ,  C07H17/02 ,  C07H19/056

摘要： An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

公开(公告)号：US11896673B2

公开(公告)日：2024-02-13

申请号：US17188583

申请日：2021-03-01

申请人： NORTH CAROLINA STATE UNIVERSITY

发明人： Zhen Gu ,  Chao Wang

IPC分类号： A61K38/28 ,  A61K47/54 ,  A61K47/69 ,  C07H13/08 ,  A61K47/60 ,  A61K47/64 ,  A61P3/10 ,  A61K9/00 ,  A61K35/18

CPC分类号： A61K47/549 ,  A61K9/0021 ,  A61K35/18 ,  A61K38/28 ,  A61K47/60 ,  A61K47/64 ,  A61K47/6937 ,  A61P3/10 ,  C07H13/08

摘要： Disclosed herein is a glucose-responsive insulin delivery system based on the interaction between the glucose-modified insulin and glucose transporters (GLUTs) on erythrocytes (or red blood cells, RBCs). After being conjugated with glucose, insulin can efficiently bind to RBC membranes. The binding is reversible in the setting of hyperglycemia, resulting in fast release of insulin and subsequent drop of blood glucose (BG) level in vivo. In some embodiments, the delivery vehicle can include: 1) intravenously injectable polymeric nanoparticles (˜100 nm in diameter) coated with RBC membrane and loaded with glucose-modified insulin and/or 2) painless microneedle (MN) patches loaded with the complex of GLUT and glucose-modified insulin.

公开(公告)号：US11827663B2

公开(公告)日：2023-11-28

申请号：US17127979

申请日：2020-12-18

申请人： The Johns Hopkins University

发明人： Kevin J. Yarema ,  Christopher T. Saeui ,  Alfredo Quinones-Hinojosa ,  Sagar Ramesh Shah

IPC分类号： A61K31/7008 ,  A61K31/7024 ,  C07H13/04 ,  A61K45/06 ,  A61K31/35 ,  C07H13/08 ,  C12Q1/48

CPC分类号： C07H13/04 ,  A61K31/35 ,  A61K31/7024 ,  A61K45/06 ,  C07H13/08 ,  C12Q1/485 ,  C12Y207/07023 ,  C12Y207/07083 ,  G01N2333/9125 ,  G01N2500/04 ,  G01N2500/10 ,  G01N2500/20

摘要： Disclosed are UAP inhibitors to inhibit glucose flux in the hexosamine biosynthetic pathway and methods of treating a disease using the inhibitors.

公开(公告)号：US20230322837A1

公开(公告)日：2023-10-12

申请号：US18323272

申请日：2023-05-24

申请人： SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD.

发明人： Jun XU ,  Mengjiao HAO ,  Yuting ZHANG ,  Hao CHEN

IPC分类号： C07H13/08 ,  C07D311/36 ,  A61P31/14 ,  C07C69/88

CPC分类号： C07H13/08 ,  A61P31/14 ,  C07C69/88 ,  C07D311/36

摘要： Provided are stellate compounds that target spike proteins and have a significant anti-SARS-CoV-2 ability and a certain broad spectrum. Such molecules and salts thereof have at least one basic unit R(X)n, which binds at an orthotopic binding site such as an MD domain or an allosteric site, to a virus containing spike proteins or a virus having spike proteins on its surface, thereby preventing coronavirus or other viruses which express spike proteins on their surfaces from invading host cells, and preventing the occurrence of viral infection. In addition, interaction of the molecules and salts thereof with vitamin K-dependent proteins in the human body inhibits the expression of vitamin K so as to inhibit blood coagulation in the human body, thereby treating thrombosis caused by coronavirus and producing a curative effect for pneumonia caused by a severe viral infection.

公开(公告)号：US20230219991A1

公开(公告)日：2023-07-13

申请号：US18180421

申请日：2023-03-08

申请人： ADJUVANCE TECHNOLOGIES, INC. ,  MEMORIAL SLOAN KETTERING CANCER CENTER

发明人： David Y. GIN ,  Eric CHEA ,  Alberto FERNANDEZ-TEJADA ,  Jeffrey GARDNER ,  Jason LEWIS ,  Philip LIVINGSTON ,  J. Tyler MARTIN ,  Lars NORDSTROEM ,  Naga Vara Kishore PILLARSETTY ,  Govind RAGUPATHI ,  Derek TAN

IPC分类号： C07H1/00 ,  C07H13/04 ,  A61K39/02 ,  C07H13/06 ,  C07H13/08 ,  A61K31/7024 ,  C07J63/00 ,  A61K39/39 ,  A61P31/04 ,  A61K39/08 ,  A61K39/00 ,  A61K39/10

CPC分类号： C07H1/00 ,  C07H13/04 ,  A61K39/099 ,  C07H13/06 ,  C07H13/08 ,  A61K31/7024 ,  C07J63/008 ,  A61K39/39 ,  A61P31/04 ,  A61K39/08 ,  A61K2039/55583 ,  A61K2039/10

摘要： The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.

公开(公告)号：US20180327436A1

公开(公告)日：2018-11-15

申请号：US15774081

申请日：2016-11-04

申请人： ADJUVANCE TECHNOLOGIES, INC.

发明人： David Y. GIN (Deceased) ,  Eric CHEA ,  Alberto FERNANDEZ-TEJADA ,  Jeffrey GARDNER ,  Jason LEWIS ,  Philip LIVINGSTON ,  J. Tyler MARTIN ,  Lars NORDSTROEM ,  Naga Vara Kishore PILLARSETTY ,  Govind RAGUPATHI ,  Derek TAN

IPC分类号： C07H1/00 ,  C07H13/08 ,  A61K31/7024 ,  A61P31/04 ,  A61K39/08 ,  A61K39/02 ,  A61K39/39

CPC分类号： C07H1/00 ,  A61K31/7024 ,  A61K39/08 ,  A61K39/099 ,  A61K39/39 ,  A61K2039/10 ,  A61K2039/55583 ,  A61P31/04 ,  C07H13/08

摘要： The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.

公开(公告)号：US20180319748A1

公开(公告)日：2018-11-08

申请号：US16035502

申请日：2018-07-13

申请人： Respivert Limited ,  Topivert Pharma Limited

发明人： Thomas Matthew BAKER ,  Matthew Colin Thor FYFE ,  Geraint JONES ,  Stephen Malcolm THOM

IPC分类号： C07D213/74 ,  C07F9/6512 ,  C07H19/048 ,  A61K31/44 ,  A61K31/506 ,  A61K31/675 ,  C07D213/80 ,  C07D401/12 ,  C07D239/47 ,  C07D413/12 ,  C07H13/08 ,  C07H15/26 ,  C07F9/6558 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/4545 ,  A61K31/4439 ,  A61K31/706 ,  A61K31/553 ,  A61K31/551 ,  A61K31/541 ,  C07D405/12 ,  C07D453/02 ,  A61K31/4412 ,  A61K31/505 ,  A61K31/444 ,  A61K45/06 ,  A61K31/635 ,  A61K31/4375 ,  A61K31/7052

CPC分类号： C07D213/74 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/4412 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/505 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/551 ,  A61K31/553 ,  A61K31/635 ,  A61K31/675 ,  A61K31/7052 ,  A61K31/706 ,  A61K45/06 ,  C07D213/80 ,  C07D239/47 ,  C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07D453/02 ,  C07F9/58 ,  C07F9/59 ,  C07F9/65031 ,  C07F9/6512 ,  C07F9/65583 ,  C07H13/08 ,  C07H15/26 ,  C07H19/048 ,  A61K2300/00

摘要： There are provided compounds of formula IIb, wherein: LG1 represents imidazolyl, chloro, or aryloxy; and Z1 represents a structural fragment of formula V: wherein R2 to R4, R5a, L and X1 to X3 have meanings given in the description, or a salt or protected derivative thereof, wherein said protected derivative is a compound in which the carboxyl moiety of R4 is protected as a C1-8 alkyl ester. The compounds have antiinflammatory activity, for example through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

公开(公告)号：US09956240B2

公开(公告)日：2018-05-01

申请号：US14880098

申请日：2015-10-09

申请人： University of South Carolina

发明人： Edward L. D'Antonio ,  Jennifer D'Antonio

IPC分类号： A61K31/7008 ,  C07H5/06 ,  C07H13/04 ,  C07H13/08 ,  C07H13/12

CPC分类号： A61K31/7008 ,  C07H5/06 ,  C07H13/04 ,  C07H13/08 ,  C07H13/12 ,  Y02A50/414 ,  Y02A50/415

摘要： Methods for treating a mammal that is infected by a parasitic organism are provided, along with pharmaceutical compositions and compounds. The method includes administering to the mammal the pharmaceutical composition of FIG. 1, where: R1, R2, R3, and R4 comprises, independently, H, OH, NH2, SH, a halogen, or an organic group or a derivative thereof; X1 is O, NH, CH2, or S; m is 0 or 1; X2 comprises an organic linkage, such as CH2; n is an integer from 0 to 10; and R5 comprises an aromatic organic group.

公开(公告)号：US20180092935A1

公开(公告)日：2018-04-05

申请号：US15834428

申请日：2017-12-07

申请人： SyneuRx International (Taiwan) Corp.

发明人： Guochuan Emil Tsai ,  Ching-Cheng Wang ,  Tien-Lan Hsieh ,  Yi-Wen Mao

IPC分类号： A61K31/7024 ,  A61P25/28 ,  A61P25/18 ,  A61P25/24 ,  A61P25/30 ,  A61P25/16 ,  A61P9/00 ,  A61P1/16 ,  A61P5/50 ,  A61P11/06 ,  A61P11/00 ,  A23L33/10 ,  A23L33/00

CPC分类号： A61K31/7024 ,  A23L33/10 ,  A23L33/105 ,  A23L33/30 ,  A23V2002/00 ,  A61K36/185 ,  A61K36/22 ,  A61K36/48 ,  A61K36/49 ,  A61K36/82 ,  A61K36/87 ,  A61K38/26 ,  A61K45/06 ,  A61P1/16 ,  A61P5/50 ,  A61P9/00 ,  A61P11/00 ,  A61P11/06 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  C07H1/08 ,  C07H13/08 ,  Y02A50/411 ,  A61K2300/00

摘要： Compositions (e.g., pharmaceutical compositions, nutraceutical compositions or medical food compositions) comprising tannic acids, particularly tannic acids which are D-amino acid oxidase inhibitor with superior potency, purity and safety profile; and uses thereof for treating CNS disorder and obesity disorders including diabetes, hyperglycemia, hyperlipidemia or hypercholesterolemia.

公开(公告)号：US09920088B2

公开(公告)日：2018-03-20

申请号：US14437611

申请日：2013-10-18

申请人： Peking University ,  University of Macau

发明人： Demin Zhou ,  Maorong Yu ,  Sulong Xiao ,  Fei Yu ,  Yiyun Peng ,  Yunyan Qiu ,  Lihe Zhang ,  Yitao Wang

IPC分类号： C07H15/256 ,  A61K31/56 ,  A61K31/704 ,  C07H13/08 ,  C07J63/00

CPC分类号： C07H15/256 ,  A61K31/56 ,  C07H13/08 ,  C07J63/008

摘要： The present invention relates to the use of triterpenoid derivatives for the preparation of a medicament for preventing or treating influenza diseases, in which the substituents are as defined in the specification. The triterpenoid derivatives of the present invention have obvious inhibition effect on influenza virus, and are capable of obviously preventing influenza virus from entering cells, and can be used for preventing or treating influenza.